Saturday 17 October 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.
2.55
0.01
−0.39%
Follow APYX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.37 | 2.89 | 2.72 | 1.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(56.41) | (282.18) | (56.85) | (24.66) | |
P/B ratio |
17.75 | 12.33 | 9.70 | 14.34 | |
Price to Tangible BV |
18.05 | 12.51 | 9.82 | 14.79 | |
EV/Sales |
3.65 | 3.12 | 2.95 | 2.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.08) | (22.14) | (19.48) | (12.56) | |
EV/FCF |
(19.32) | (19.38) | (17.10) | (11.12) | |
Quick Ratio |
4.41 | 4.65 | 4.15 | 3.47 | |
Current Ratio |
5.68 | 5.80 | 5.00 | 4.44 | |
Net Debt/EBITDA |
(4.79) | (5.58) | 13.45 | (14.21) | |
Debt/Assets |
57.85% | 55.68% | 52.16% | 60.36% | |
Debt/Equity |
3.19 | 2.68 | 2.35 | 5.69 | |
Asset Turnover |
0.98 | 0.91 | 0.80 | 0.81 | |
Operating CF/Net income |
1.08 | 0.27 | 1.95 | 1.78 | |
Capex/Depreciation |
(0.34) | (0.30) | (1.24) | (3.16) | |
Interest Coverage |
(1.30) | (0.67) | 0.01 | (0.59) | |
Research and Development Expense of Revenue |
5.71% | 6.12% | 4.93% | 6.22% | |
Selling, General and Administrative Expense of Revenue |
71.18% | 64.62% | 57.63% | 64.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.74% | 2.50% | 2.61% | 4.12% | |
Graham Net Nets |
0.02 | 0.03 | 0.04 | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.45%) | (5.96%) | (7.71%) | (16.82%) | |
Free Cash Flow Yield |
(5.61%) | (5.57%) | (6.34%) | (10.89%) | |
Revenue per Share |
0.32 | 0.29 | 0.47 | 0.32 | |
Operating CF per Share |
(0.08) | (0.01) | (0.06) | (0.09) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.08) | (0.01) | (0.07) | (0.10) | |
Cash per Share |
0.63 | 0.71 | 0.77 | 0.62 | |
Shareholders Equity per Share |
0.25 | 0.30 | 0.36 | 0.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.25 | 0.30 | 0.36 | 0.15 | |
Free Cash Flow |
(3.56) | (0.63) | (2.80) | (4.05) | |
Working Capital |
43.80 | 45.35 | 46.77 | 37.81 | |
Capital Expenditures |
(0.07) | (0.06) | (0.27) | (0.52) | |
Net Current Asset Value |
3.17 | 4.86 | 6.46 | (2.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.43 | 12.20 | 16.13 | 13.02 | |
Average Payables |
2.54 | 2.47 | 2.84 | 2.57 | |
Average Inventory |
9.47 | 8.61 | 8.08 | 9.07 | |
Average Assets |
59.63 | 61.59 | 65.84 | 59.04 | |
Average Common Equity |
9.27 | 11.87 | 14.58 | 8.64 |
Columns are period end dates